CLVLF (Clinuvel Pharmaceuticals) Gross-Profit-to-Asset % : 28.67% (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Clinuvel Pharmaceuticals's annualized Gross Profit for the quarter that ended in Dec. 2024 was $43.44 Mil. Clinuvel Pharmaceuticals's average Total Assets over the quarter that ended in Dec. 2024 was $151.53 Mil. Therefore, Clinuvel Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 28.67%.

Clinuvel Pharmaceuticals Gross-Profit-to-Asset % Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Gross-Profit-to-Asset % Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

31.79

47.49

42.16

40.37

36.59

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															35.33	47.49	30.73	42.21	28.67

Competitive Comparison of Clinuvel Pharmaceuticals's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Gross-Profit-to-Asset % falls into.

Save Embed

Clinuvel Pharmaceuticals Gross-Profit-to-Asset % Calculation

Clinuvel Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2024 )	/	( (Total Assets (A: Jun. 2023 )	+	Total Assets (A: Jun. 2024 ))	/ count )
	=	51.857	/	( (130.009	+	153.469)	/ 2 )
	=	51.857	/	141.739
	=	36.59 %

Clinuvel Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	43.44	/	( (153.469	+	149.592)	/ 2 )
	=	43.44	/	151.5305
	=	28.67 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Clinuvel Pharmaceuticals Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.